Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The associated price target remains the same with Yen5,500.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Koichi Mamegano has given his Buy rating due to a combination of factors, primarily focusing on the promising phase 3 trial results for Takeda Pharmaceutical’s orexin receptor agonist, oveporexton, aimed at treating narcolepsy type 1 (NT1). The trials, presented at World Sleep 2025, demonstrated statistically significant and clinically meaningful improvements in NT1 symptoms, with good safety and tolerability profiles. This progress in late-stage development is seen as a positive indicator for the company’s future performance.
Additionally, the trials showed that both high and low doses of oveporexton were effective, providing optimal treatment options for patients. The absence of serious adverse events and the resolution of common side effects like insomnia further support the drug’s potential. The sales estimate for oveporexton, projected at ¥405.7 billion by FY3/37, reflects a strong market opportunity, reinforcing the Buy rating with a price objective of ¥5,500.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TKPHF in relation to earlier this year.